On December 10, 2021, Kolon Life Science Inc. closed the transaction. The company has raised KRW 25,000,000,000 in its Series 3 unregistered coupon nonguaranteed private convertible bond in final tranche bringing total proceeds to KRW 40,000,000,000.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21,950 KRW | 0.00% | -1.79% | -14.59% |
1st Jan change | Capi. | |
---|---|---|
-14.59% | 182M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.81% | 248B | |
-1.35% | 219B | |
+11.03% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- A102940 Stock
- News Kolon Life Science Inc.
- Kolon Life Science Inc. announced that it has received KRW 40 billion in funding